Soltanipour Soheil, Hasandokht Tolou, Soleimani Robabeh, Mahdavi-Roshan Marjan, Jalali Mir Mohammad
School of Medicine, Guilan University of Medical Sciences, Rasht, Guilan, Iran.
Kavosh Cognitive Behavior Sciences and Addiction Research Center, School of Medicine, Shafa Hospital, Guilan University of Medical Sciences, Rasht, Guilan, Iran.
Rev Diabet Stud. 2019;15:60-70. doi: 10.1900/RDS.2019.15.60. Epub 2019 Oct 24.
This study aimed to assess the effects of soy consumption on glucose metabolism in patients with type 2 diabetes.
A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Review (PRISMA) principles. Literature published between 1990 and 2019 was searched. Primary outcomes were the effect of soy on fasting plasma glucose (FPG), insulin, and HbA1c. The data were pooled using random effects models. Heterogeneity was assessed using Cochran's Q and I statistics. Also, the Cochrane Collaboration's tool for assessing risk of bias was used, and sensitivity analysis and meta-regression were conducted. Publication bias was evaluated using Egger and Begg tests.
Sixteen randomized clinical trials (RCTs) with a total of 471 participants were regarded as eligible and included in the study. Soy consumption had no significant effects on FPG, insulin, and HbA1c. After the "trim-and-fill" method was applied, soy revealed a significant effect size on FPG (adjusted Cohen's d: -0.18; p = 0.03). Also, subgroup analyses using studies with parallel design showed a significant improvement (moderate effect size) in FPG and insulin. Sensitivity analysis indicated the robustness of our findings. Among secondary outcomes, the results showed a significant effect of soy on HOMA-IR and total cholesterol levels.
Although this systematic review and meta-analysis indicated no beneficial effects of soy consumption on FPG, insulin, and HbA1c in patients with type 2 diabetes, pooling of parallel studies showed different results from crossover studies. The quality of evidence revealed low levels of confidence for primary outcomes. Therefore, further research is recommended.
本研究旨在评估食用大豆对2型糖尿病患者糖代谢的影响。
按照系统评价的首选报告项目(PRISMA)原则进行系统评价。检索了1990年至2019年发表的文献。主要结局是大豆对空腹血糖(FPG)、胰岛素和糖化血红蛋白(HbA1c)的影响。使用随机效应模型汇总数据。使用Cochran's Q和I统计量评估异质性。此外,使用Cochrane协作网的偏倚风险评估工具,并进行敏感性分析和Meta回归。使用Egger检验和Begg检验评估发表偏倚。
共有16项随机临床试验(RCT)、471名参与者被认为符合条件并纳入本研究。食用大豆对FPG、胰岛素和HbA1c无显著影响。应用“修剪和填充”方法后,大豆对FPG显示出显著的效应量(校正后的Cohen's d:-0.18;p = 0.03)。此外,使用平行设计研究的亚组分析显示FPG和胰岛素有显著改善(中等效应量)。敏感性分析表明我们研究结果的稳健性。在次要结局中,结果显示大豆对HOMA-IR和总胆固醇水平有显著影响。
尽管这项系统评价和Meta分析表明,食用大豆对2型糖尿病患者的FPG、胰岛素和HbA1c没有有益影响,但平行研究的汇总结果与交叉研究不同。证据质量显示对主要结局的置信度较低。因此,建议进一步开展研究。